FDA Committee Recommends Novartis Psoriasis Drug Approval


The FDA's Dermatologic and Ophthalmic Drugs Advisory Committee has recommended the approval of Novartis' first-in-class secukinumab therapy for moderate-to-severe plaque psoriasis.

The FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee has recommended the approval of Novartis’ first-in-class secukinumab therapy for moderate-to-severe plaque psoriasis.

"Moderate-to-severe psoriasis is a serious condition where patients suffer from skin lesions that cause itching, pain, and scaling. There is a need for novel therapies, as not all treatments are appropriate or effective in every patient,” said Vas Narasimhan, global head of development for Novartis, in a statement. “Today's recommendation…brings us one step closer to delivering an innovative, new treatment option for people suffering from moderate-to-severe psoriasis. We look forward to working with the FDA as it finalizes its review."

Novartis submitted a Biologics License Application for secukinumab in October 2013, and the FDA is expected to act upon it in early 2015.

The regulatory committee’s recommendation for the drug’s approval followed the completion of a phase 3 clinical program involving 4 placebo-controlled studies that examined the efficacy and safety of secukinumab 150 mg and 300 mg in patients with moderate-to-severe plaque psoriasis. In those pivotal studies, the drug met its primary and secondary endpoints of showing significant skin clearance while exhibiting no major safety issues.

Secukinumab is the first selective interleukin-17A (IL-17A) inhibitor to be considered by the FDA for the treatment of moderate-to-severe plaque psoriasis in adult patients. IL-17A is a protein involved in the development of psoriasis.

The FDA committee based its recommendation on the results of 10 phase 2 and phase 3 clinical studies that included nearly 4000 psoriasis patients.

Related Videos
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image credit: Andrea Izzotti
Inflation Reduction Act is shown using the text and the US flag - Image credit: Andrii | stock.adobe.com
Pharmacy Interior | Image Credit: Tyler Olson - stock.adobe.com
Male pharmacist selling medications at drugstore to a senior woman customer | Image Credit: Zamrznuti tonovi - stock.adobe.com
Pharmacist assists senior woman in buying medicine in pharmacy - Image credit: Drazen | stock.adobe.com
Pharmacy, medicine and senior woman consulting pharmacist on prescription. Healthcare, shopping and elderly female in consultation with medical worker for medication box, pills or product in store - Image credit: C Daniels/peopleimages.com | stock.adobe.com
Image credit: fidaolga - stock.adobe.com
Pharmacists checking inventory at hospital pharmacy- Image credit: Jacob Lund | stock.adobe.com
Young male pharmacist giving prescription medications to senior female customer in a pharmacy | Image Credit: Zamrznuti tonovi - stock.adobe.com
© 2023 MJH Life Sciences

All rights reserved.